Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that patients receiving epratuzumab reported clinically meaningful improvements in health-related quality of life that were sustained over approximately 4 years of treatment.
The study is the extension arm of the two ALLEVIATE trials, with 29 ALLEVIATE patients enrolled in the extension study to receive two infusions of 360 mg/m2 epratuzumab on day 1 and day 8 of 12-week cycles. Immunomedics has licensed the rights to the development and commercialization of epratuzumab to UCB in all autoimmune diseases. The effect of epratuzumab on HRQoL was measured using the 36-item Short Form Health Survey.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org